| Issue | Title | |
| Vol 2007, No 84 (2007) | Therapy Focus: Anaemia in Chronic Kidney Disease and Cancer | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | Therapy Focus: Angiogenesis | Abstract |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Therapy Focus: Anticancer | Abstract |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Therapy Focus: Antiplatelet Therapy | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 74 (2006) | Therapy Focus: Atherosclerosis | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Therapy Focus: Atopic Eczema | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Therapy Focus: Attention Deficit Hyperactivity Disorder | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Therapy Focus: Biodefence | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 60 (2005) | Therapy Focus: Cancer Vaccines | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Therapy Focus: Colorectal Cancer | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | Therapy Focus: COPD | Abstract |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Therapy Focus: Cystic Fibrosis | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | Therapy Focus: Diabetes | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 25 (2002) | Therapy Focus: Diabetes | Abstract |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Therapy Focus: Diagnosing Prostate Cancer | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | Therapy Focus: Dyslipidemia and the Statins | Abstract |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | Therapy Focus: Erectile Dysfunction | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 72 (2006) | Therapy Focus: Hypoxia-Selective Agents as Anticancer Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Therapy Focus: Inflammatory Bowel Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Therapy Focus: Insomnia | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Therapy Focus: Interferons | Abstract |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Therapy Focus: Malaria | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Therapy Focus: Migraine | Abstract |
| Business Review Editor | ||
| Vol 2005, No 66 (2005) | Therapy Focus: Neuropathic Pain | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 91 (2008) | Therapy focus: Osteoarthritis | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Therapy Focus: Osteoporosis | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | Therapy Focus: Osteoporosis and the Women’s Health Market | Abstract |
| Business Review Editor | ||
| Vol 2007, No 80 (2007) | Therapy Focus: Parkinson#8217;s Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 92 (2008) | Therapy Focus: Prostate Cancer | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Therapy Focus: Psoriasis | Abstract |
| Business Review Editor | ||
| Vol 2005, No 63 (2005) | Therapy Focus: Rheumatoid Arthritis | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 64 (2005) | Therapy Focus: Schizophrenia | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 40 (2003) | Therapy Focus: Severe Acute Respiratory Syndrome | Abstract |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Therapy Focus: Severe Sepsis and Septic Shock | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 77 (2006) | Therapy Focus: Spinal Cord Injury | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | Therapy Focus: Stroke | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | Therapy Focus: Tuberculosis | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 76 (2006) | Therapy Focus: Wound Care | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | Theravance and GSK in Alliance to Develop Respiratory Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 2 (2015) | Theravance Finds a Good Match for its Phase III-Ready Nebulised COPD Therapy in Mylan | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 3 (2020) | Thermo Fisher Acquires Molecular Diagnostics Specialist Qiagen for US$11.5 B | Abstract html pdf |
| Michelle Liu | ||
| Vol 2004, No 53 (2004) | TopoTarget AS | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | TorreyPines Chooses Consolidation over IPO | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 51 (2004) | Toyama Chemical Co. Ltd. | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | Transition Licenses Diabetes Regenerative Therapy to Novo Nordisk | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Trends within the Drug Delivery Sector | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Tularik and Amgen in Oncology Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Tysabri (natalizumab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 6 (2012) | UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 2 (2022) | UCB Acquires Zogenix to Bolster its Epilepsy Portfolio | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2005, No 63 (2005) | UCB and Imclone Strike Antibody Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 9 (2010) | UCB Buys Rights to Two Parkinson’s Disease Therapies from Synosia Therapeutics | Abstract |
| Editorial Team | ||
| Vol 2014, No 11 (2014) | UCB Divests its US Generics Arm to Advent International and Avista Capital Partners for US$1525 M | Abstract |
| Heather Cartwright & Smita Mishra | ||
| Vol 2023, No 3 (2023) | UCB Enters into Drug Discovery Collaboration with Aitia for Huntington’s Disease | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2006, No 76 (2006) | UCB SA | Abstract |
| Business Review Editor | ||
| Vol 2004, No 49 (2004) | UCB Tenders US$2.7 B Offer to Acquire Celltech | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 10 (2019) | UCB’s Bets on Complement Diseases with US$2.1 B Ra Pharma Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 62 (2005) | UK Acquisitions Hit the Headlines | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | UK Oncology plc | Abstract |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | UK Spin-off Acquired by Roche for Multi-Million Figure | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2023, No 2 (2023) | UniQure Pays US$10 M Upfront for Apic Bio’s ALS Gene Therapy | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 11 (2018) | United Therapeutics Licenses Arena’s Ralinepag for US$800 M Upfront | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 6 (2012) | Upsher-Smith to Take Over CNS Partner Proximagen | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 77 (2006) | US Companies Expand Distribution of Veritas® | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 99 (2008) | US Election Will Impact New Drug Development Worldwide Forever | Abstract html |
| Fintan Walton | ||
| Vol 2002, No 27 (2002) | US Licensing Strategy of Small and Mid-Sized European Pharmaceutical Companies | Abstract |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | Using Options in Pharmaceutical Licensing | Abstract |
| Business Review Editor | ||
| Vol 2012, No 2 (2012) | Valeant Agrees to Buy Eyetech to Strengthen its Ophthalmology Business | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 6 (2013) | Valeant Aims to Compete in Ophthalmology with US$8.7 B Bausch & Lomb Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Valeant Continues its Acquisition Spree with Agreement to Buy Janssen’s Ortho Dermatologics Division | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 6 (2011) | Valeant Continues its Expansion in Central and Eastern Europe with Sanitas Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 10 (2012) | Valeant Expands in Ophthalmology with Acquisition of QLT’s Visudyne ® | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 57 (2005) | Valeant Expands Neurology Franchise through Acquisition of Xcel | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 4 (2012) | Valeant Further Expands in Russia with Natur Produkt Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 4 (2013) | Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 99 (2008) | Valeant Licenses Epilepsy Drug to GSK | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2015, No 9 (2015) | Valeant Licenses Rights to AstraZeneca’s Troubled Psoriasis Drug Brodalumab | Abstract html html |
| Heather Cartwright & Shruti Desai | ||
| Vol 2011, No 9 (2011) | Valeant Outbids Paladin Labs with US$78 M Offer to Acquire Afexa Life Sciences | Abstract |
| Hetather Cartwright | ||
| Vol 2010, No 5 (2010) | Valeant Pharma acquires Aton Pharma for USD 318 M | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 99 (2008) | Valeant Pharmaceuticals’ De-Globalisation Strategy Sees the Sale of European Operations | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2015, No 3 (2015) | Valeant Settles for Second Best with US$14.5 B Salix Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 2 (2011) | Valeant to Acquire PharmaSwiss and Expand its Presence in Central and Eastern Europe | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Valeant to Buy Sanofi’s Dermik Skincare Unit for US$425 M | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | Validation and Value: The Risk of RNAi Therapeutics | Abstract |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Valtaxin (valrubicin) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Valuation Methodologies in Biotech | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 12 (2017) | Value for Money? An Analysis of Five Product-Driven M&A Deals | Abstract pdf |
| Heather Cartwright & Dan Roberts | ||
| Vol 2012, No 9 (2012) | Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 81 (2007) | VASTox Signs Drug Discovery Deals Worth a Combined US$1.3 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | VaxGen Amends Agreement with Genentech for AIDSVAX | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Vectibix (panitumumab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 4 (2016) | Vectura Acquires SkyePharma for US$628 M to Lead in Inhalation Devices | Abstract pdf html |
| Heather Cartwright & Rohit Khera | ||
| Vol 2013, No 5 (2013) | Vectura Forays into China by Forming JV with Tianjin KingYork and Zendex Bio Strategy | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 61 (2005) | Vectura Group plc | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Vectura to Take Over Innovata | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 3 (2014) | Vectura Ventures into Nebuliser Market with Activaero Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 34 (2003) | Vencor to Distribute Efoora’s Rapid HIV Test Worldwide | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Venture Capitalist | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 91 (2008) | Vernakalant | Abstract pdf |
| Business Review Editor | ||
| 2401 - 2500 of 2581 Items | << < 20 21 22 23 24 25 26 > >> | |